

Ulcerative colitis – etrasimod – initial grandfather authority application

When to use this form

Use this form to apply for **initial grandfather** PBS-subsidised etrasimod for patients with moderate to severe ulcerative colitis who have received non-PBS-subsidised treatment with etrasimod for the same condition prior to **1 October 2024**.

Important information

Initial grandfather applications to start PBS-subsidised treatment must be in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Applications for **balance of supply** can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Under no circumstances will phone approvals be granted for moderate to severe ulcerative colitis **initial grandfather** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is **ONLY** for **initial grandfather** treatment.

After a written authority application for **initial grandfather** treatment has been approved, applications for **continuing** treatment can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Treatment specifics

The assessment of the patient's response to the course of treatment must be conducted within the time frame specified in the restriction. Where a demonstration of response is not conducted within the required time frame, the patient will be deemed to have failed treatment with that particular PBS-subsidised biological medicine.

A patient who has experienced a serious adverse reaction of a severity necessitating permanent treatment withdrawal is not considered to have failed treatment with that particular PBS-subsidised biological medicine.

For more information

Go to servicessaustralia.gov.au/healthprofessionals

11 Prior to commencing treatment with this drug for this condition, the patient had responded inadequately to:

azathioprine at a dose of at least 2 mg/kg daily for at least 3 consecutive months

or

6-mercaptopurine at a dose of at least 1 mg/kg daily for at least 3 consecutive months

or

a tapered course of oral steroids, starting at a dose of at least 40 mg prednisolone (or equivalent) over a 6 week period, **followed by** at least 3 consecutive months of an appropriately dosed thiopurine agent

or

each of the above 3 therapies due to severe intolerance leading to permanent treatment discontinuation

or

not applicable due to contraindications to **each of the above 3** therapies.

12 Prior to commencing non-PBS-subsidised treatment with this drug for this condition, the patient had:

a baseline Mayo clinic score ≥ 6

Mayo clinic score

Date of assessment (DD MM YYYY)

or

a baseline partial Mayo clinic score ≥ 6 , provided the rectal bleeding and stool frequency subscores were both ≥ 2

Partial Mayo clinic score

Rectal bleeding subscore

Stool frequency subscore

Date of assessment (DD MM YYYY)

or

a documented history of moderate to severe refractory ulcerative colitis, where a Mayo clinic or partial Mayo clinic baseline assessment is not available

Checklist

13  The relevant attachments need to be provided with this form.

- Details of the proposed prescription(s).
- The completed baseline Mayo clinic or partial Mayo clinic calculation sheet before initiating treatment (if available), including the date of assessment.

Privacy notice

14 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application. Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicessaustralia.gov.au/privacypolicy

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicessaustralia.gov.au/hpos

15 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine.
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application.
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.
- the information I have provided in this form is complete and correct.

I understand that:

- giving false or misleading information is a serious offence.

I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

Prescriber's signature (**only** required if returning by post)



Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at servicessaustralia.gov.au/hpos
- or
- by post (signature required) to
Services Australia
Complex Drugs Programs
Reply Paid 9826
HOBART TAS 7001